Oxygen Consumption and Extracellular Acidification Rate in Adipogenic Differentiated Human Mesenchymal Stromal/Stem Cells.
Olmedo-Suárez MA., Sánchez-Ramírez E., Del Toro-Rios X., Noriega LG., Aguilar-Arnal L.
Laboratory Study, published in Methods Mol Biol (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Methods Mol Biol (2025)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40445283
- DOI
- 10.1007/978-1-0716-4607-6_10
Abstract (original English)
Human mesenchymal stem/stromal cells (hMSCs) constitute a primary cell source in adipogenesis, playing a pivotal role in the generation of new adipocytes. This process is accompanied by substantial metabolic shifts in hMSCs, notably characterized by a transition from glycolytic to oxidative metabolism. Monitoring metabolic alterations during adipogenic differentiation can be achieved through the assessment of extracellular flux parameters, such as the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR). In this study, we provide a comprehensive protocol for differentiating hMSCs into the adipogenic lineage, with an emphasis on tracking differentiation stages through extracellular flux measurements. We determined the cellular metabolic status throughout the adipogenic differentiation by assessing OCR and ECAR to gauge mitochondrial respiration and glycolytic activity, respectively, using a Seahorse XFe96 extracellular flux analyzer.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.